Ansell Healthcare Europe NV/SA
—
Riverside Business Park – Block J
Boulevard International 55
1070 Brussels, Belgium

T. + 32 (0)2 528 74 00
F. + 32 (0)2 528 74 01
Email: info.europe@ansell.com
www.ansell.com

EU DECLARATION OF CONFORMITY

This EU Declaration of Conformity is issued under the sole responsibility of Ansell Healthcare Europe NV.

Manufacturer Name/Address: Ansell Healthcare Europe NV
Boulevard International 55
Brussels
B-1070
Belgium

SRN Number: BE-MF-000000691

Risk Class: Class IIa

Intended Purpose: A sterile medical device intended as a surgical glove and a protective barrier when worn on the hands of healthcare providers at the surgical site. It is used mainly as a two-way barrier to protect patient and staff from microorganisms. This is a single-use device.

EMDN Code and Description: T01010102 - Non-Powdered Latex Surgical Gloves

Basic UDI DI: 5414566 ELMOIST2018 MS

Product Name(s):

Product Name	Product Code	Size	Region(s)
ENCORE® Latex Moisturizing	2018655	5.5	Americas
ENCORE® Latex Moisturizing	2018660	6	Americas
ENCORE® Latex Moisturizing	2018665	6.5	Americas
ENCORE® Latex Moisturizing	2018670	7	Americas
ENCORE® Latex Moisturizing	2018675	7.5	Americas
ENCORE® Latex Moisturizing	2018680	8	Americas
ENCORE® Latex Moisturizing	2018685	8.5	Americas
ENCORE® Latex Moisturizing	2018690	9	Americas

Conformity Assessment Procedure: Annex IX.

CE Certificate No: MDR 763361.

Certified through the British Standards Institution, Notified Body Number 2797.

Ansell Healthcare Europe NV/SA
—
Riverside Business Park – Block J
Boulevard International 55
1070 Brussels, Belgium

T. + 32 (0)2 528 74 00
F. + 32 (0)2 528 74 01
Email: info.europe@ansell.com
www.ansell.com

We hereby declare that the medical device(s) specified above meet the provision of the Regulation (EU) MDR 2017/745 for medical devices.

Signed on behalf of the Manufacturer

Ansell Healthcare Europe NV
Riverside Business Park - Block J
Bld Internationalelaan 55
B-1070 Brussels
BELGIUM

Name:	Samantha Marshall
Position:	Director Regulatory Affairs Medical EMEA & APAC
Date:	02 March 2023
Place of Issue:	Nuneaton, England
Revision:	MED\MDR\ELMOIST\001